Today we would like to bring to your attention a new emerging company that we feel can be tremendous in its growing industry.

This company is in the pharmaceutical industry, which is one of the biggest industries, revenue wise.

More over, this company has great technical indicators in our opinion, which make it a possibly great short term trade.

The company that we are announcing to our readers is CANNABIS SCIENCE INC (Public, OTC:CBIS).

CBIS is developing products to heal illnesses and conditions such as arthritis, asthma, influenza, pain management, stress management, etc.

Moreover, CBIS is in a unique position to pursue the development of blood pressure and cancer medications. The endocannabinoid system normally regulates blood pressure through its capacity to dilate blood vessels and reduce adrenergic stimuli.

CBIS is uniquely positioned to explore insights that indicate an intrinsic link between novel cancer and HIV technologies and the cannabinoid system. Published experiments by a leading AIDS researcher, Dr. Donald Abrams, suggest that counter to conventional wisdom, smoked marijuana does not result in an increased HIV viral load. In fact, there were suggestions of a reduced viral load. We expect to show that our pharmaceuticals will enhance biochemical markers that are indicative of a successful HIV therapy based on recent paradigm breaking discoveries.

CBIS works with world authorities on phytocannabinoid science developing cannabis-based therapeutics that will holistically promote health by restoring biochemical balance. By adhering to underlying scientific principles, the Company will manipulate all-pervasive phytocannabinoid processes to target a variety of disparate illnesses.

Technical Stats:

CBIS has a low float level, of about 65,500,000 shares. This can have a greater effect on shareholder value than higher float levels.

CBIS recently consolidated at .06 level, however recently it has broken resistance which is symbolizing bullish investor attitude toward shares of this company.

Today, it was risen more than 19% after hitting low levels. We believe this can continue in the next coming days.

News:

Cannabis Science Acquires New 9,500 Square Foot Denver Facility for Researching, Developing, Testing, and Producing Medical Cannabis for Patients

CBIS, a pioneering U.S. biotech company developing pharmaceutical cannabis products, is pleased to announce that it has entered into a long-term lease on a 9,500 square foot facility in Denver, Colorado, that will become its corporate offices, as well as serving as a research facility for developing, testing, and producing medical cannabis for patients in compliance with the new Colorado laws regulating medical marijuana in the state.

Dr. Robert Melamede, Ph.D., Cannabis Science President and CEO, stated, “Having all of these operations in one secure, state-licensed facility will greatly increase our ability to provide patients with affordable cannabis based medicines and to determine what they find to be most effective in treating their medical problems. In addition to organic herbal cannabis, we will also be producing extracts, infusions such as tinctures, as well as edibles, which many patients prefer when they have confidence in their source. Quality control and the ability to develop standardized products are the essential keys to moving forward with both medical marijuana under state laws, as well as being the basis of any pharmaceutical formulations we will submit for FDA clinical trials.”

Richard Cowan, Cannabis Science CFO, explained, “The revenue potential from this facility is obviously very significant, and we will make public our estimates on the projected revenue in the near future, but, as with our previously announced acquisitions in Colorado and Montana, our main focus will remain on R&D. As Dr. Melamede has pointed out, previously new biotech companies have never known whether their proposed products were safe and effective until they were submitted for FDA clinical trials. Now Cannabis Science, working in states with medical marijuana laws, is changing the paradigm. We will know that the products we submit for clinical trials will be what the patients want and need. This new facility is a key part of our corporate strategy.”

Breaking News:

Cannabis Science Comments on NY Times Article Regarding Major Support From Veterans Affairs for Medical Marijuana; Cannabis Scie

Full article: Here

CBIS is at the moment an undervalued stock, we hope you have been able to see its immense value after reading this report. Please conduct your own Due Diligence and consider adding CBIS to your portfolios.

• Bookmark on Delicious
• Digg this post
• Recommend on Facebook
• share via Reddit
• Share with Stumblers
• Tweet about it
• Subscribe to the comments on this post

This entry was posted on Tuesday, July 27th, 2010 at 1:08 am and is filed under WPS Stock Alerts . You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.